Quoin Pharmaceuticals Ltd expected to post a loss of $6.07 a share - Earnings Preview

Quoin Pharmaceuticals

09/05/2025 16:49

Quoin Pharmaceuticals Ltd QNRX.OQ, QNRX.O is expected to show no change in quarterly revenue when it reports  results on May 13 for the period ending March 31 2025

​LSEG's mean analyst estimate for Quoin Pharmaceuticals Ltd is for a loss of $6.07 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Quoin Pharmaceuticals Ltd is $60.20​, above​ its last closing price of $6.26. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-16.10
-12.25
Beat
23.9
Sep. 30 2024
-16.30
-17.27
-16.45
Beat
4.7
Jun. 30 2024
-20.98
-21.35
-13.65
Beat
36.1​
Mar. 31 2024
-26.10
-26.60
-38.85
Missed
-46.1
​​Dec. 31 2023
-81.02
-72.80
Beat
10.2
Sep. 30 2023
-1.01 hundred
-95.27
-68.25
Beat
28.4​
Jun. 30 2023
-98.50
-98.70
-74.55
Beat
24.5
Mar. 31 2023
-1.23 hundred
-1.19 hundred
-1.43 hundred
Missed
-20.3

This summary was machine generated May 9 at 15:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)